Diabetes 54:3587-3591, 2005
© 2005 by the American Diabetes Association, Inc.
Single Nucleotide Polymorphisms in the Peroxisome Proliferator–Activated Receptor Gene Are Associated With Skeletal Muscle Glucose Uptake
Markku Vänttinen1,
Pirjo Nuutila2,3,
Teemu Kuulasmaa1,
Jussi Pihlajamäki1,
Kirsti Hällsten2,
Kirsi A. Virtanen2,
Riikka Lautamäki2,
Pauliina Peltoniemi2,
Teemu Takala2,3,
Antti P.M. Viljanen2,
Juhani Knuuti2, and
Markku Laakso1
1 Department of Medicine, University of Kuopio, Kuopio, Finland
2 Positron Emission Tomography Centre, University of Turku, Turku, Finland
3 Department of Medicine, University of Turku, Turku, Finland
The peroxisome proliferator–activated receptors (PPARs) belong to a superfamily of nuclear receptors. It includes PPAR- , a key regulator of fatty acid oxidation and energy uncoupling, universally expressed in different tissues. The PPAR- gene (PPARD) maps to 6p21.2-p21.1 and has 11 exons and spans 35 kbp. We investigated the effects of single nucleotide polymorphisms (SNPs) of PPARD on whole-body, skeletal muscle, and subcutaneous adipose tissue glucose uptake in 129 healthy individuals using the hyperinsulinemic-euglycemic clamp technique combined with fluorine-18–labeled fluorodeoxyglucose ([18F]FDG) and positron emission tomography (PET). Three of six SNPs of PPARD and their haplogenotypes were significantly associated with whole-body insulin sensitivity. [18F]FDG-PET scanning indicated that SNPs of PPARD primarily affected insulin sensitivity by modifying glucose uptake in skeletal muscle but not in adipose tissue. Our results give evidence that SNPs of PPARD regulate insulin sensitivity particularly in skeletal muscle.
Address correspondence and reprint requests to Markku Laakso, MD, Academy Professor, Department of Medicine, University of Kuopio, 70210 Kuopio, Finland. E-mail: markku.laakso{at}kuh.fi
Abbreviations:
[18F]FDG, fluorine-18–labeled fluorodeoxyglucose; PET, positron emission tomography; PPAR, peroxisome proliferator–activated receptor; PPARD, PPAR- gene; SNP, single nucleotide polymorphism; WBGU, whole-body glucose uptake

CiteULike Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
E. Nilsson, P. Poulsen, M. Sjogren, C. Ling, M. Ridderstrale, L. Groop, and A. Vaag
Regulation of skeletal muscle PPAR{delta} mRNA expression in twins
J. Physiol.,
November 1, 2007;
584(3):
1011 - 1017.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. K. Kramer, L. Al-Khalili, B. Guigas, Y. Leng, P. M. Garcia-Roves, and A. Krook
Role of AMP Kinase and PPAR{delta} in the Regulation of Lipid and Glucose Metabolism in Human Skeletal Muscle
J. Biol. Chem.,
July 6, 2007;
282(27):
19313 - 19320.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Stefan, C. Thamer, H. Staiger, F. Machicao, J. Machann, F. Schick, C. Venter, A. Niess, M. Laakso, A. Fritsche, et al.
Genetic Variations in PPARD and PPARGC1A Determine Mitochondrial Function and Change in Aerobic Physical Fitness and Insulin Sensitivity during Lifestyle Intervention
J. Clin. Endocrinol. Metab.,
May 1, 2007;
92(5):
1827 - 1833.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. Andrulionyte, P. Peltola, J.-L. Chiasson, M. Laakso, and for the STOP-NIDDM Study Group
Single Nucleotide Polymorphisms of PPARD in Combination With the Gly482Ser Substitution of PGC-1A and the Pro12Ala Substitution of PPARG2 Predict the Conversion From Impaired Glucose Tolerance to Type 2 Diabetes: The STOP-NIDDM Trial.
Diabetes,
July 1, 2006;
55(7):
2148 - 2152.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2005 by the American Diabetes Association.
|
|
| |
|